Related Experiment Video
Updated: Jul 4, 2025

Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System
Published on: October 16, 2013
Diagnostic Performance of a Fecal Calprotectin Assay as a Biomarker for Mayo Endoscopic Subscore in Ulcerative
Tanita Suttichaimongkol1,2, Nayantara Coelho-Prabhu1, David H Bruining1
1Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
Fecal calprotectin (FC) effectively assesses ulcerative colitis (UC) endoscopic activity. An FC cutoff of 60 mcg/g reliably distinguishes inactive disease (MES 0) from active inflammation (MES 1-3) in UC patients.
Area of Science:
- Gastroenterology
- Clinical Biomarkers
- Inflammatory Bowel Disease Research
Background:
- Fecal calprotectin (FC) is a key biomarker for evaluating ulcerative colitis (UC) endoscopic severity.
- Optimal FC cutoffs for specific Mayo Endoscopic Subscores (MES) require further clarification.
Purpose of the Study:
- To determine precise FC cutoffs for correlating with distinct MES in UC patients.
- To validate FC's utility in assessing endoscopic disease activity and predicting clinical remission.
Main Methods:
- Retrospective review of 177 UC patients' electronic medical records and FC levels.
- Endoscopic images were independently graded for MES by three IBD specialists.
- FC levels were analyzed for correlation with MES and clinical remission.
Main Results:
- FC strongly correlated with MES (r=0.709, P<.01).
- An FC cutoff of 60 mcg/g accurately differentiated MES 0 from MES 1-3 (AUC=0.901).
- FC cutoffs of 110 mcg/g and 310 mcg/g distinguished higher levels of endoscopic activity.
Conclusions:
- FC is a reliable marker for endoscopic inflammation in UC.
- An FC cutoff of 60 mcg/g is effective for distinguishing inactive disease from active inflammation.
- FC aids in assessing UC endoscopic activity and guiding treatment decisions.
More Related Videos
Related Concept Videos
Serum Laboratory Studies, Stool Test, Breath Test
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Ulcerative Colitis in IBD

